Search all medical codes
Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
CPT4 code
Name of the Procedure:
Infectious Agent Genotype Analysis by Nucleic Acid (DNA or RNA); HIV-1, Reverse Transcriptase and Protease Regions
Summary
This procedure tests for specific genetic variations in the HIV-1 virus. It examines two key regions of the virus, the reverse transcriptase, and protease regions, to understand how the virus may respond to different treatments.
Purpose
- Addresses the medical condition of HIV-1 infection.
- Helps determine the most effective antiretroviral therapy by identifying resistance mutations in the HIV-1 virus.
Indications
- HIV-positive patients with a high viral load.
- Patients experiencing failure in current antiretroviral therapy.
- People newly diagnosed with HIV to guide initial treatment.
Preparation
- No special preparations or fasting required.
- Blood sample is typically required.
- Inform the healthcare provider of any current medications.
Procedure Description
- Blood samples are collected from the patient.
- The sample is processed in a laboratory to extract DNA or RNA.
- Specific regions of the HIV-1 genome (reverse transcriptase and protease regions) are amplified and sequenced.
- The genetic sequences are analyzed to detect mutations that may confer drug resistance.
- Equipment includes PCR machines and sequencing technology.
- No anesthesia or sedation is necessary.
Duration
Typically, it takes a few hours to a few days for the analysis to be completed in the lab.
Setting
Performed in a specialized laboratory equipped for genetic analysis.
Personnel
- Phlebotomist or nurse to draw blood.
- Laboratory technicians or molecular biologists to process and analyze the samples.
Risks and Complications
- Minor discomfort or bruising at the blood draw site.
- Rare risk of infection at the puncture site.
- Laboratory errors, though infrequent, can lead to inaccurate results.
Benefits
- Personalized HIV treatment plans optimized for better outcomes.
- Improved management of HIV medication, reducing the risk of resistance.
- Quick turnaround allows timely decisions on therapy adjustments.
Recovery
- No recovery time needed for the blood draw.
- Patients can resume normal activities immediately after the sample collection.
- Follow-up involves discussing test results with the healthcare provider for further treatment planning.
Alternatives
- Phenotypic resistance testing: assesses the growth of the virus in response to medications.
- Integrated therapy without prior genotype testing, though less precise.
- Pros and cons: Genotypic testing is faster and more specific, but phenotypic testing may be more comprehensive.
Patient Experience
- The patient might feel a small pinch during the blood draw.
- Little to no discomfort after the blood draw.
- Emotional relief from receiving precise treatment recommendations.